Programs
AM-Pharma is a clinical stage biopharmaceutical company developing Alkaline Phosphatase biologic therapies.
Alkaline Phosphatase (AP) has a key role in protecting organs against inflammation and tissue damage, acting as a detoxifying agent by dephosphorylating pro-inflammatory substances.
Acute Kidney Injury
In our lead program, we are preparing for a Phase III pivotal study and subsequent commercialization of recAP as a transformative treatment for Acute Kidney Injury (AKI).
Inflammatory Bowel Disease
We are developing an oral formulation of recAP as a potential treatment option for Ulcerative Colitis, in which patients show reduced AP expression in the gut.
Hypophosphatasia
We are exploring the use of recAP in the treatment of Hypophosphatasia (HPP), a metabolic orphan disease which affects bone formation and calcification.
RECAP
We have developed recombinant human Alkaline Phosphatase (recAP), constructed from two human isoforms of AP, as an innovative disease modifying therapeutic. recAP is optimized for high stability and activity and has been evaluated in clinical trials.
Molecular model of recombinant Alkaline Phosphatase (AP), recAP, a homodimer consisting of the activity domains from human intestinal AP (displayed in white) and the stability or crown domains from placental AP (red). (courtesy of Prof J.L. Millan, Sanford Burnham Institute Medical Research, UCSD, La Jolla, CA)
